GSK responds to 60 Minutes | Related Video
- Details
- Category: GlaxoSmithKline
![GlaxoSmithKline GlaxoSmithKline](/images/stories/logo/gsk.gif)
First two clinical phase III studies confirm the profile of nalmefene
- Details
- Category: Lundbeck
![Lundbeck Lundbeck](/images/stories/logo/lundbeck.gif)
European Commission approves Tasigna® for treatment of patients with newly diagnosed Ph+ chronic myeloid leukemia
- Details
- Category: Novartis
![Novartis Novartis](/images/stories/logo/novartis_b.gif)
Sanofi-aventis Acquires from Ascendis Pharma Worldwide Rights on Drug-Delivery Technology
- Details
- Category: Sanofi
![Sanofi-aventis Sanofi-aventis](/images/stories/logo/sanofi-aventis.gif)
Pfizer Submits Applications to Expand the Use of Prevnar 13® to Adults 50 and Older
- Details
- Category: Pfizer
![Pfizer Pfizer](/images/stories/logo/pfizer_b.gif)
Novo Nordisk A/S and Emisphere Technologies, Inc. Announce Licence Agreement
- Details
- Category: Novo Nordisk
![Novo Nordisk Novo Nordisk](/images/stories/logo/novonordisk_b.gif)
Bristol-Myers Squibb and Oncolys BioPharma Enter Global Licensing Agreement
- Details
- Category: Bristol-Myers Squibb
![Bristol-Myers Squibb Bristol-Myers Squibb](/images/stories/logo/bms.gif)
More Pharma News ...
- Genzyme Details Market Potential of Alemtuzumab for MS
- EpiTherapeutics and Abbott Enter Into Oncology Collaboration on Epigenetic Targets
- Merck KGaA and sanofi-aventis to Investigate Novel Combinations Against Cancer
- Roche provides update on Avastin following reviews in Europe and the United States
- Lundbeck enters into drug discovery collaboration with Zenobia and Vernalis
- Pfizer Extends Tender Offer To Acquire King Pharmaceuticals, Inc.
- Lundbeck to establish a strong, dedicated sales force behind Lexapro® in China